Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 13;49(2):45. doi: 10.3892/or.2023.8482

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Yang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — PTBP1 knockdown decreases the sensitivity of SF-treated liver cancer cells to ferroptosis. PTBP1 (A) mRNA and (B) protein level changes following SF treatment (5 µM, 24 h). (C and D) SF inhibited the growth of liver cancer cells as revealed by the results of the CCK-8 assay. (E-G) Changes in the levels of ferroptosis indicators in liver cancer cells after SF treatment. Following silencing of PTBP1, the levels of (E) iron and (F) MDA significantly decreased, whereas that of (G) intracellular GSH significantly increased. (H) Representative confocal microscopic images of C11-BODIPY 581/591 staining in SF-treated liver cancer cells. *P<0.05, **P<0.01 and ***P<0.001 (Student's t-test). PTBP1, polypyrimidine tract-binding protein 1; SF, sorafenib; CCK-8, Cell Counting Kit-8; MDA, malondialdehyde; GSH, glutathione; NC, negative control; si-, small interfering RNA.